SAN CLEMENTE, Calif., May 14, 2012 /PRNewswire/ -- ICU Medical, (NASDAQ:ICUI) today announced that it would “vigorously seek to collect damages” as a result of its patent infringement victory over RyMed. ICU Medical filed a lawsuit in 2007 to stop RyMed Technologies from selling its patent-infringing In-Vision Plus needlefree connector. And, although RyMed modified its device, the company still pursued the infringement claims against both the original and current devices. On December 17, 2010, ICU Medical obtained a Federal jury verdict that RyMed’s devices infringe on two of ICU Medical’s patents and ICU Medical’s patents are valid.
The Court granted ICU Medical a limited new trial on the narrow question of whether RyMed’s current device literally infringes one other of ICU Medical’s patents (‘866), and last week, a jury found that it does not. ICU Medical has not decided whether it will appeal this limited verdict.
“The new verdict does not impact any portion of the earlier verdict that RyMed’s original and current devices infringe ICU’s patents,” explained Alison Burcar, ICU Medical’s Vice President of Product Development. “In the next phase of this case, we will establish the monetary damages caused by RyMed’s infringing activities, and then vigorously seek to collect those damages.”
Media Contact:Tom McCall
Vice President, Marketing
949-291-8959
tmccall@icumed.com
About ICU Medical, Inc.: ICU Medical, Inc. develops, manufactures and sells innovative medical devices used in vascular therapy, oncology and critical care applications. ICU Medical’s products improve patient outcomes by helping prevent bloodstream infections and protecting healthcare workers from exposure to infectious diseases or hazardous drugs. The company’s complete product line includes custom I.V. systems, closed delivery systems for hazardous drugs, needle-free I.V. connectors, catheters and cardiac monitoring systems. ICU Medical is headquartered in San Clemente, California.
SOURCE ICU Medical, Inc.
